Supernus Pharmaceuticals, Inc. (SUPN): Price and Financial Metrics


Supernus Pharmaceuticals, Inc. (SUPN)

Today's Latest Price: $30.59 USD

0.65 (2.17%)

Updated Jan 25 4:00pm

Add SUPN to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 239 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

SUPN Stock Summary

  • With a price/earnings ratio of 12.2, Supernus Pharmaceuticals Inc P/E ratio is greater than that of about merely 19.6% of stocks in our set with positive earnings.
  • Over the past twelve months, SUPN has reported earnings growth of 39.28%, putting it ahead of 78.62% of US stocks in our set.
  • The volatility of Supernus Pharmaceuticals Inc's share price is greater than that of merely 18.97% US stocks with at least 200 days of trading history.
  • Stocks that are quantitatively similar to SUPN, based on their financial statements, market capitalization, and price volatility, are PAR, CEMI, VREX, VSTM, and AVID.
  • Visit SUPN's SEC page to see the company's official filings. To visit the company's web site, go to www.supernus.com.

SUPN Stock Price Chart Interactive Chart >

Price chart for SUPN

SUPN Price/Volume Stats

Current price $30.59 52-week high $30.66
Prev. close $29.94 52-week low $13.12
Day low $29.36 Volume 482,738
Day high $30.65 Avg. volume 599,427
50-day MA $24.09 Dividend yield N/A
200-day MA $22.69 Market Cap 1.61B

Supernus Pharmaceuticals, Inc. (SUPN) Company Bio


Supernus Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The company was founded in 2005 and is based in Rockville, Maryland.

SUPN Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$30.59$99.78 233%

Below please find a table outlining a discounted cash flow forecast for SUPN, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Supernus Pharmaceuticals Inc ranked in the 75th percentile in terms of potential gain offered. Moreover, under all the scenarios we modelled, the output consistently forecasted positive returns. As for the metrics that stood out in our discounted cash flow analysis of Supernus Pharmaceuticals Inc, consider:

  • Its compound free cash flow growth rate, as measured over the past 5.51 years, is 0.36% -- higher than 72.76% of stocks in our DCF forecasting set.
  • Supernus Pharmaceuticals Inc's weighted average cost of capital (WACC) is 8%; for context, that number is higher than only 18.67% of tickers in our DCF set.
  • As a business, Supernus Pharmaceuticals Inc experienced a tax rate of about 16% over the past twelve months; relative to its sector (Healthcare), this tax rate is higher than 70.53% of stocks generating free cash flow.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%227%
1%230%
2%233%
3%237%
4%240%
5%243%

Want more companies with a valuation profile/forecast similar to that of Supernus Pharmaceuticals Inc? See VTRS, SUWN, CI, LHCG, and UHS.


SUPN Latest News Stream


Event/Time News Detail
Loading, please wait...

SUPN Latest Social Stream


Loading social stream, please wait...

View Full SUPN Social Stream

Latest SUPN News From Around the Web

Below are the latest news stories about Supernus Pharmaceuticals Inc that investors may wish to consider to help them evaluate SUPN as an investment opportunity.

Supernus Pharmaceuticals (SUPN) Investor Presentation - Slideshow

The following slide deck was published by Supernus Pharmaceuticals, Inc. in conjunction with this event....

SA Transcripts on Seeking Alpha | January 20, 2021

The Daily Biotech Pulse: Bausch Health Issues Positive Pre-Announcement, Acorda Streamlines Operations

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 12) AbbVie Inc (NYSE: ABBV ) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Aldeyra Therapeutics Inc (NASDAQ: ALDX ) Alkermes Plc (NASDAQ: ALKS ) AtriCure Inc. (NASDAQ: ATRC ) Bioanalytical Systems, Inc. (NASDAQ: BASI ) BIOLASE Inc (NASDAQ: BIOL ) (announced an agreement to expand laser adoption and hands-on training programs in targeted geographies) CareDx Inc (NASDAQ: CDNA ) Celsius Holdings, Inc. (NASDAQ: CELH ) DermTech Inc (NASDAQ: DMTK ) Dyne Therapeutics Inc (NASDAQ: DYN ) Edap Tms SA (NASDAQ: EDAP ) Evelo Biosciences Inc (NASDAQ: EVLO ) EXACT Sciences Corporation (NASDAQ: EXAS ) Eyenovia Inc (NASDAQ: EYEN ) Genetron Holdings Ltd – ADR (NASDAQ...

Benzinga | January 13, 2021

The Daily Biotech Pulse: GSK, Vir To Start COVID-19 Antibody Study, Novartis In-Licenses BeiGene's Cancer Drug, Earnings Preannouncements Continue

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 11) 10X Genomics Inc (NASDAQ: TXG ) AbbVie Inc (NYSE: (ABBV) Aldeyra Therapeutics Inc (NASDAQ: ALDX ) Atea Pharmaceuticals, Inc. (NASDAQ: AVIR ) AtriCure Inc. (NASDAQ: ATRC ) (reacted to the company's preliminary fourth-quarter results) Bioanalytical Systems, Inc. (NASDAQ: BASI ) Biodesix Inc (NASDAQ: BDSX ) C4 Therapeutics Inc (NASDAQ: CCCC ) CareDx Inc (NASDAQ: CDNA ) (announced preliminary fourth-quarter results) Celsius Holdings, Inc. (NASDAQ: CELH ) Chimerix Inc (NASDAQ: CMRX ) Curis, Inc. (NASDAQ: CRIS ) Dyne Therapeutics Inc (NASDAQ: DYN ) (announced positive preclinical data from its myotonic dystrophy type 1 program) Edap Tms SA (NASDAQ:...

Benzinga | January 12, 2021

Exact Sciences Scores Relative Strength Rating Upgrade; Hits Key Threshold

Exact Sciences saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 75 to 85. As you try to find the best stocks to buy and watch, be sure to pay attention to relative price strength. Exact Sciences is now considered extended and out of buy range after clearing a 139.36 buy point in a second-stage cup with handle.

Yahoo | January 12, 2021

Supernus to Present at J.P. Morgan 39th Annual Healthcare Conference

ROCKVILLE, Md., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company's management will present at the J.P. Morgan 39th Annual Healthcare Conference on Thursday, January 14, 2021, at 9:10 a.m. ET, and will be available for virtual investor meetings. A live webcast of the presentation can be accessed by visiting Events & Presentations in the Investor Relations section on the Company's website at www.supernus.com. An archived replay of this webcast will be available for 60 days on the Company's website after the conference.About Supernus Pharmaceuticals, Inc.Supernus Pharmaceuticals, Inc. is a p...

Yahoo | January 6, 2021

Read More 'SUPN' Stories Here

SUPN Price Returns

1-mo N/A
3-mo 62.37%
6-mo 31.85%
1-year 29.78%
3-year -26.20%
5-year 177.08%
YTD 21.58%
2020 6.07%
2019 -28.60%
2018 -16.64%
2017 57.82%
2016 87.87%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8814 seconds.